Standout Papers

The blockade of immune checkpoints in c... 1993 2026 2004 2015 10.1k
  1. The blockade of immune checkpoints in cancer immunotherapy (2012)
    Drew M. Pardoll Nature reviews. Cancer
  2. STATs in cancer inflammation and immunity: a leading role for STAT3 (2009)
    Hua Yu, Drew M. Pardoll et al. Nature reviews. Cancer
  3. Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy (2015)
    Suzanne L. Topalian, Charles G. Drake et al. Cancer Cell
  4. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. (1993)
    Glen Dranoff, Elizabeth M. Jaffee et al. Proceedings of the National Academy of Sciences
  5. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (2010)
    Julie R. Brahmer, Charles G. Drake et al. Journal of Clinical Oncology
  6. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy (2016)
    Suzanne L. Topalian, Janis M. Taube et al. Nature reviews. Cancer
  7. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy (2014)
    Janis M. Taube, Alison Klein et al. Clinical Cancer Research
  8. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape (2012)
    Janis M. Taube, Robert A. Anders et al. Science Translational Medicine
  9. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment (2006)
    Hua Yu, Marcin Kortylewski et al. Nature reviews. Immunology
  10. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses (2009)
    Shaoguang Wu, Ki‐Jong Rhee et al. Nature Medicine
  11. Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1 (2011)
    Eric V. Dang, Huang‐Yu Yang et al. Cell
  12. The Central Role of CD4+ T Cells in the Antitumor Immune Response (1998)
    Kenneth E. Hung, Robert J. Hayashi et al. The Journal of Experimental Medicine
  13. The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints (2014)
    Nicolás J. Llosa, Michael Cruise et al. Cancer Discovery
  14. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity (2012)
    Suzanne L. Topalian, Charles G. Drake et al. Current Opinion in Immunology
  15. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis (2002)
    Guilian Niu, Kenneth L. Wright et al. Oncogene
  16. Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens (1994)
    Alex Y. Huang, Paul T. Golumbek et al. Science
  17. Role of LAG-3 in Regulatory T Cells (2004)
    Ching-Tai Huang, Creg J. Workman et al. Immunity
  18. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells (2003)
    Tianhong Wang, Guilian Niu et al. Nature Medicine
  19. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. (1996)
    Frank Guarnieri, Kevin F. Staveley-O’Carroll et al. PubMed
  20. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity (2005)
    Marcin Kortylewski, Maciej Kujawski et al. Nature Medicine
  21. Expression of Programmed Death 1 Ligands by Murine T Cells and APC (2002)
    Tomohide Yamazaki, Hisaya Akiba et al. The Journal of Immunology
  22. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response (1990)
    Eric R. Fearon, Drew M. Pardoll et al. Cell
  23. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria (2018)
    Christine M. Dejea, Payam Fathi et al. Science
  24. B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells (2001)
    Mizuto Otsuji, Kevin Gorski et al. The Journal of Experimental Medicine
  25. IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway (2009)
    Lin Wang, Tangsheng Yi et al. The Journal of Experimental Medicine
  26. Neoadjuvant checkpoint blockade for cancer immunotherapy (2020)
    Suzanne L. Topalian, Janis M. Taube et al. Science
  27. Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4 (1991)
    Paul T. Golumbek, Audrey J. Lazenby et al. Science
  28. Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma (2013)
    Sofía Lyford-Pike, Shiwen Peng et al. Cancer Research
  29. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade (2015)
    Juan Fu, David B. Kanne et al. Science Translational Medicine
  30. Does the Immune System See Tumors as Foreign or Self? (2003)
    Drew M. Pardoll Annual Review of Immunology
  31. A fixed site of DNA replication in eucaryotic cells (1980)
    Drew M. Pardoll, Bert Vogelstein et al. Cell
  32. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression (1998)
    Kevin F. Staveley-O’Carroll, Eduardo M. Sotomayor et al. Proceedings of the National Academy of Sciences
  33. The role of CD4+ T cell responses in antitumor immunity (1998)
    Drew M. Pardoll, Suzanne L. Topalian Current Opinion in Immunology
  34. Persistently Activated Stat3 Maintains Constitutive NF-κB Activity in Tumors (2009)
    Heehyoung Lee, Andreas Herrmann et al. Cancer Cell
  35. Supercoiled loops and eucaryotic DNA replication (1980)
    Bert Vogelstein, Drew M. Pardoll et al. Cell
  36. Mechanisms of Immune Evasion by Tumors (2006)
    Charles G. Drake, Elizabeth M. Jaffee et al. Advances in immunology
  37. Developing a pro-regenerative biomaterial scaffold microenvironment requires T helper 2 cells (2016)
    Kaitlyn Sadtler, Brian W. Allen et al. Science
  38. The Bacteroides fragilis Toxin Gene Is Prevalent in the Colon Mucosa of Colorectal Cancer Patients (2014)
    Annemarie Boleij, Elizabeth M. Hechenbleikner et al. Clinical Infectious Diseases
  39. Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade (2019)
    Steve Lu, Julie E. Stein et al. JAMA Oncology
  40. Mechanisms regulating PD-L1 expression on tumor and immune cells (2019)
    Shuming Chen, George A. Crabill et al. Journal for ImmunoTherapy of Cancer
  41. Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy (2023)
    Suzanne L. Topalian, Patrick M. Forde et al. Cancer Cell
  42. Cancer therapy with antibodies (2024)
    Suman Paul, Maximilian F. Konig et al. Nature reviews. Cancer

Immediate Impact

77 by Nobel laureates 74 from Science/Nature 355 standout
Sub-graph 1 of 13

Citing Papers

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Effects of extracellular matrix viscoelasticity on cellular behaviour
2020 StandoutNature
4 intermediate papers

Works of Drew M. Pardoll being referenced

Divergent immune responses to synthetic and biological scaffolds
2018
Tissue matrix arrays for high-throughput screening and systems analysis of cell function
2015
and 1 more

Author Peers

Author Last Decade Papers Cites
Drew M. Pardoll 46168 44257 23146 398 81.6k
Gordon J. Freeman 53470 37868 14403 418 81.0k
Robert D. Schreiber 47711 33142 20381 378 78.3k
Mark J. Smyth 52200 36937 19880 592 80.1k
Laurence Zitvogel 41768 30721 31005 488 77.2k
Lloyd J. Old 46929 33262 32823 714 84.6k
Jedd D. Wolchok 29224 44357 15851 558 63.2k
Arlene H. Sharpe 47078 28206 16005 406 74.3k
James P. Allison 49382 38454 12845 480 70.9k
Wolf H. Fridman 30637 27029 16241 524 56.0k
Michael T. Lotze 25546 16922 20053 495 56.3k

All Works

Loading papers...

Rankless by CCL
2026